Those include the UK Prospective Diabetes Study (UKPDS), the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) trial, the DIGAMI-2 study, and, more recently, the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial [55–59]. The gene discussed is INS; the disease is myocardial infarction.